noom vs weight watchers glp-1 vs. (2026): An Evidence-Based Comparison Choosing A Weight Loss Program

In early 2022, I recall seeing another shift in utilization from GLP-1s with less weight loss benefit (Victoza, Soliqua, Trulicity, etc.) to Ozempic and Mounjaro, creating a consolidation in usage that along with other factors likely led to minor rebate improvement but increased initial costs

A negative RET test essentially eliminates the MEN 2 contraindication, providing definitive clearance from the genetic risk perspective

Prathigna Thambi Feb 5 5 min read Getting back to the gym after the holidays is always a challenge

The kidney composite reduction is consistent across CKD severity strata

These factors reinforce the need for individualized treatment plans rather than broad, unsupervised use

2022;13(Suppl 1):517